Skip to main content
. 2011 Oct 21;1(1):112–123. doi: 10.1159/000333017

Table 2.

Enrollment characteristics of the AKI cohort according to the 5 CYBA gene polymorphisms

Characteristic rs8854 genotypt
P value rs3794624 genotypes
P value rs4673 genotypes
P value rs4782390 genotypes
P value rsl049255 genotypes
P value
n: GG 227 GA/AA 35 GG 118 GA/AA 139 CC 107 CT/TT 155 AA 123 AT/TT 137 AA 143 AG/GG 113
Age, years 66 (15) 66 (18) 0.81 67 (15) 65 (16) 0.38 65 (16) 67 (15) 0.32 66 (15) 65 (16) 0.61 65 (15) 67 (16) 0.53
Males, % 52 60 0.35 52 54 0.72 50 55 0.40 55 50 0.36 54 52 0.80
Race, % 0.83 0.49 0.11 0.003 0.006
White 90 91 90 91 87 93 85 96 95 85
Black 7 6 9 6 8 6 12 2 3 12
Other 3 3 2 3 5 1 3 2 2 3
Contributing cause
of AKI, % 0.35 0.46 0.34 0.89 0.66
Ischemic 29 20 25 30 26 30 26 30 26 32
Nephro toxic 15 23 20 13 15 16 17 15 17 15
Septic 9 11 11 8 6 12 10 9 8 10
Multifactorial/other 33 40 32 36 40 29 33 34 37 30
Coexisting conditions, %
DM 45 43 0.86 46 43 0.68 44 45 0.93 40 48 0.18 48 42 0.34
Heart failure 17 9 0.20 16 16 0.95 14 17 0.46 20 13 0.16 15 18 0.62
Cirrhosis 7 11 0.31 9 5 0.26 9 7 0.53 7 8 0.65 8 4 0.12
CLD 19 14 0.51 15 21 0.25 21 17 0.44 21 16 0.29 19 18 0.81
CKD 68 69 0.94 69 68 0.87 70 65 0.52 71 66 0.43 69 65 0.48
APACHE II score 20 (7) 18 (5) 0.176 20 (6) 20 (7) 0.84 19 (6) 20 (7) 0.21 20 (7) 19 (6) 0.23 19 (6) 21 (7) 0.01
Sepsis, % 45 26 0.03 44 42 0.81 37 47 0.09 42 45 0.62 43 43 0.95
Shock, % 30 11 0.02 24 31 0.20 24 30 0.29 22 34 0.04 30 25 0.35
Serum creatinine, mg/dl
Baseline value 1.6 (0.8) 1.4 (0.5) 0.37 1.6 (0.8) 1.5 (0.6) 0.82 1.6 (0.6) 1.5 (0.8) 0.56 1.6 (0.8) 1.5 (0.6) 0.07 1.5 (0.6) 1.6 (0.8) 0.53
Enrollment value 3.6 (1.8) 3.5 (1.4) 0.96 3.7 (1.9) 3.5 (1.6) 0.46 3.6 (1.7) 3.5 (1.8) 0.55 3.7 (1.8) 3.4 (1.7) 0.20 3.4 (1.6) 3.6 (1.9) 0.36
Peak 4.4 (2.7) 4.1 (1.8) 0.61 4.7 (3.2) 4.1 (1.9) 0.08 4.3 (2.1) 4.4 (2.9) 0.65 4.5 (3.0) 4.2 (2.2) 0.34 4.4 (3.0) 4.3 (2.0) 0.72
Discharge 2.5 (1.7) 2.3 (1.6) 0.37 2.5 (1.8) 2.5 (1.7) 0.89 2.5 (1.6) 2.5 (1.8) 0.85 2.7 (1.9) 2.4 (1.5) 0.12 2.4 (1.7) 2.7 (1.7) 0.18
Urine output, Vday 1.2 (1.1) 1.5 (1.2) 0.25 1.2 (1.0) 1.3 (1.2) 0.69 1.3 (1.2) 1.2 (1.0) 0.33 1.4 (1.1) 1.2 (1.0) 0.12 1.2 (1.0) 1.4 (1.1) 0.39
AKI stage at enrollment, % 0.47 0.11 0.41 0.68 0.87
Stage 1 43 43 36 49 43 43 41 46 44 42
Stage 2 4 9 5 4 7 3 45 5 5 4
Stage 3 53 49 59 47 50 54 55 49 51 54
Oxidative stress markers
Plasma nitro-tyrosine, nM 12 (9, 23) 11 (10, 24) 0.29 12 (9, 24) 12 (9, 22) 0.45 12 (9,21) 12 (9, 24) 0.38 12 (9, 22) 12 (8, 23) 0.30 12 (9, 23) 12 (9, 22) 0.21
Urinary 15-F2t-iso prostane, ng/mg 1.1 (0.6, 2.2) 1.1 (0.6, 4.0) 0.42 1.1 (0.6, 2.8) 1.1 (0.6, 2.0) 0.49 1.2 (0.6, 2.6) 1.0 (0.6, 2.0) 0.56 1.0 (0.5, 2.0) 1.2 (0.6, 2.4) 0.87 1.2 (0.7, 2.7) 0.9 (0.5, 1.7) 0.73

CKD = Chronic kidney disease; CLD = chronic lung disease; DM = diabetes mellitus. Continuous variables are presented as means (SD) or medians (25th, 75th percentile), and categorical variables as percentages. Missing genotyping data: rs3794624 (n = 5), rs4782390 (n = 2), and rs1049255 (n = 6).